Background: Medical image segmentation is a well-studied subject within the field of image processing. The goal of this research is to create an AI retinal screening grading system that is both accurate and fast. We introduce a new segmentation network which achieves state-of-the-art results on semantic segmentation of colour fundus photographs. By applying the network to identify anatomical markers of diabetic retinopathy (DR) and diabetic macular edema (DME) including: micro-aneurysms, haemorrhages, etc., we collect sufficient information to classify patients into R0 (no DR) and R1 or above (DR), as well as M0 (no DME) and M1 (DME).

Methods: The AI grading system was trained on public and private screening data to evaluate the presence of DR and DME. The system’s core algorithm is a novel deep learning segmentation network (W-net) that locates and segments relevant anatomical features in a retinal image. Both eyes of the patients are graded individually, based on the detected features and classified according to the standard feature-based grading protocol used in the NHS Diabetic Eye Screening Programme.

Results: The algorithm performance was evaluated with a series of patient retinal images from routine diabetic eye screenings and achieved state-of-the-art results. It correctly predicted 98% of retinopathy events (95% confidence interval [CI], 97.1-98.8) and 68.9% of maculopathy events (95% CI, 58.1-79.7). Non-disease events prediction rate was 68.6% for retinopathy and 81.3% for maculopathy.

Conclusion: This novel deep learning segmentation model trained on a colour fundus photograph data set and tested on patient data from annual diabetic retinopathy screenings can detect and classify with high accuracy the DR and DME status of a person with diabetes. The system can be easily reconfigured according to any grading protocol, without starting a long AI training procedure. The incorporation of the AI grading system can increase the graders’ productivity and improve the final outcome of the screening process.

Disclosure

O. Katz: Employee; Self; NECAM, Research Support; Self; Northgate Public Services. D. Presil: Employee; Self; NECAM, Research Support; Self; Northgate Public Services. L. Cohen: Employee; Self; NECAM, Research Support; Self; Northgate Public Services. R. Nachmani: Employee; Self; NECAM, Research Support; Self; Northgate Public Services. N. Kirshner: Employee; Self; NEC, Research Support; Self; Northgate Public Service. D. R. Owens: Advisory Panel; Self; 360 Consulting. T. H. Lev: Employee; Self; NECAM (NEC Corporation of America), Research Support; Self; Northgate Public Services. A. Hadad: Consultant; Self; Necam.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.